Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian equity markets recover
Mon, 22 Oct 11:30 am

Indian equity markets recovered from early morning losses and traded in the positive during the last two hours of trade. Sectoral indices traded mixed with IT, banking and healthcare leading the gains while FMCG and realty were on the losing side.

The BSE-Sensex is trading higher by 61 points and NSE-Nifty is trading higher by 16 points. BSE Mid Cap and BSE Small Cap indices are trading up by 0.2% and 0.4% respectively. The rupee is trading at 53.61 to the US dollar.

Indian pharma stocks are trading strong led by Wockhardt Limited and Piramal Enterprises. As per a leading daily, Sun Pharma might soon have to stop exporting its cancer drug, Lipodox to the US. This is because Johnson & Johnson's (J&J) cancer drug Doxil will now be made available for the US markets again. Earlier Johnson & Johnson was barred from supplying its cancer drug after US health regulators had found deficiencies in the production facility of the company's contract manufacturer, Ben Venue Laboratories. This resulted in shortage of the drug, used in treatment of ovarian, bone marrow and AIDS-related skin cancer. Hence, the US Food and Drug Administration (FDA) had exercised its authority to import Lipodox replacement from Sun Pharma under a temporary agreement even though Sun has not yet received full approval for Lipodox sale in the US. However, with J&J back in the market, Sun Pharma might have to pull back its supplies as it has not yet got full approval.

Auto stocks are trading in the red led by Mahindra Forgings and NRB Bearings. According to a leading financial daily, Bosch Limited is planning to double its centres to up to 3,000 outlets in the next three years. The company has recently forayed into two-wheeler servicing and has opened 11 Express Bike Service (EBS) outlets in Coimbatore and Delhi. Currently Bosch operates a total of 1,500 service centres for different types of vehicles. Of these, 500 are for passenger vehicles, while 800 are for commercial vehicles and 200 are for other types of vehicles. Last week, Bosch Automotive Aftermarkets had launched 100 service centres in North India with an aim of bridging the large gap in service network in the country. These centres will provide service to multi-brand vehicles across different segments.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian equity markets recover". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.